Skip to main content
Celcuity Inc. logo

Celcuity Inc. — Investor Relations & Filings

Ticker · CELC ISIN · US15102K1007 LEI · 25490070W7UU7W2SEY87 US Professional, scientific and technical activities
Filings indexed 484 across all filing types
Latest filing 2026-03-26 Annual Report
Country US United States of America
Listing US CELC

About Celcuity Inc.

https://www.celcuity.com/

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company's approach centers on the PI3K/AKT/mTOR (PAM) pathway, a critical signaling cascade involved in cancer cell growth and survival. Its lead product candidate, gedatolisib, is a potential first-in-class, pan-PI3K and mTORC1/2 inhibitor designed to comprehensively blockade the PAM pathway. Celcuity's pipeline is advancing treatments with a focus on breast and prostate cancers.

Recent filings

Filing Released Lang Actions
10-K - Celcuity Inc. (0001603454) (Filer)
Annual Report FY 2025
2026-03-26 English
SCHEDULE 13D/A - Celcuity Inc. (0001603454) (Subject)
Major Shareholding Notification
2026-03-24 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
4 - CELCUITY INC. (0001603454) (Filer)
Director's Dealing
2026-02-13 English
8-K Filing
Regulatory Filings
2026-02-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.